Related Experiment Video

Updated: Aug 19, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

New developments in monoclonal antibodies for cancer detection and therapy

D M Goldenberg1

  • 1Center for Molecular Medicine and Immunology, Newark, New Jersey.

CA: a Cancer Journal for Clinicians
|January 1, 1994
PubMed

Insights

Monoclonal antibodies offer targeted cancer detection and therapy. Advances like humanized antibodies enhance their effectiveness in clinical applications for various cancers.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Monoclonal antibodies (mAbs) represent a significant advancement in targeted cancer therapy.
  • Their application includes direct use or conjugation with cytotoxic agents for improved efficacy.
  • The development of humanized antibodies has further enhanced their therapeutic potential.

Purpose of the Study:

  • To summarize the current in vivo applications of monoclonal antibodies in cancer detection.
  • To review the therapeutic strategies employing monoclonal antibodies for cancer treatment.
  • To highlight recent advancements influencing the clinical utility of monoclonal antibodies.

Main Methods:

  • Review of existing literature on in vivo monoclonal antibody applications.
  • Analysis of studies detailing antibody conjugation techniques (drugs, toxins, radionuclides).
  • Examination of data on the efficacy and safety of humanized antibodies in cancer management.

Main Results:

  • Monoclonal antibodies are effective in detecting and treating several types of cancer.
  • Conjugated antibodies demonstrate enhanced specificity and potency.
  • Humanized antibodies show improved clinical outcomes and reduced immunogenicity.

Conclusions:

  • Monoclonal antibodies are a valuable tool in modern oncology.
  • Ongoing research and development, particularly in antibody engineering, continue to expand their role.
  • In vivo monoclonal antibody use is a rapidly evolving field with significant therapeutic promise.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.